Publicaciones (163) Publicaciones de Maria Luisa Lozano Almela

2024

  1. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

    British Journal of Haematology

  2. Recommendations for the future management of thrombocytopenia in patients with liver cirrhosis: A modified RAND/UCLA appropriateness method

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 1, pp. 32-50

  3. Targeted long-read sequencing identifies and characterizes structural variants in cases of inherited platelet disorders

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 3, pp. 851-859

  4. The whole is greater than the sum of its parts: Long-read sequencing for solving clinical problems in haematology

    Journal of Cellular and Molecular Medicine, Vol. 28, Núm. 3

  5. miR-146a−/− mice model reveals that NF-κB inhibition reverts inflammation-driven myelofibrosis-like phenotype

    American Journal of Hematology

2023

  1. Congenital factor XI deficiency and risk of heart failure in humans

    Journal of Thrombosis and Haemostasis

  2. Expanding therapeutic options for patients with primary immune thrombocytopenia

    The Lancet Haematology

  3. Factor XI in Carriers of Antiphospholipid Antibodies: Elevated Levels Associated with Symptomatic Thrombotic Cases, While Low Levels Linked to Asymptomatic Cases

    International Journal of Molecular Sciences, Vol. 24, Núm. 22

  4. Impact of genetic structural variants in factor XI deficiency: identification, accurate characterization, and inferred mechanism by long-read sequencing

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 7, pp. 1779-1788

  5. Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 75-92

  6. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

    Cell Reports Medicine, Vol. 4, Núm. 12

  7. Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin

    Biomedicine and Pharmacotherapy, Vol. 168

  8. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells

    Frontiers in Molecular Biosciences, Vol. 10

2022

  1. A Novel GATA1 Variant in the C-Terminal Zinc Finger Compared with the Platelet Phenotype of Patients with A Likely Pathogenic Variant in the N-Terminal Zinc Finger

    Cells, Vol. 11, Núm. 20

  2. Full-length antithrombin frameshift variant with aberrant C-terminus causes endoplasmic reticulum retention with a dominant-negative effect

    JCI Insight, Vol. 7, Núm. 19

  3. Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients

    Cancers, Vol. 14, Núm. 13

  4. MiR-146a Contributes to Thromboinflammation and Recurrence in Young Patients with Acute Myocardial Infarction

    Journal of Personalized Medicine, Vol. 12, Núm. 7

  5. New developments in the diagnosis of primary immune thrombocytopenia

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, Vol. 33

  6. Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network

    British Journal of Haematology

  7. Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease

    Blood Advances, Vol. 6, Núm. 17, pp. 5244-5255